Evotec AG (NASDAQ:EVTCY)‘s stock had its “neutral” rating reissued by analysts at Deutsche Bank AG in a research report issued on Friday.

EVTCY has been the subject of several other research reports. Zacks Investment Research raised shares of Evotec AG from a “hold” rating to a “strong-buy” rating and set a $11.00 price target for the company in a research report on Friday, August 12th. DZ Bank AG reaffirmed a “buy” rating on shares of Evotec AG in a research report on Tuesday, October 25th.

Shares of Evotec AG (NASDAQ:EVTCY) opened at 13.04 on Friday. Evotec AG has a 12 month low of $6.56 and a 12 month high of $13.04.

Evotec AG Company Profile

Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.

5 Day Chart for NASDAQ:EVTCY

Receive News & Stock Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related stocks with our FREE daily email newsletter.